Prediction of pharmacokinetics of antibiotics in patients with end-stage renal disease

被引:3
|
作者
Tajima, Naoyuki
Nagashima, Satoru
Uematsu, Toshihiko
Torii, Hideki
Tajima, Masami
Hishida, Akira
Naganuma, Hideo
机构
[1] Sankyo Co Ltd, Clin Pharmacol & Biostat Dept, Shinagawa Ku, Tokyo 1408710, Japan
[2] Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
[3] Shitoro Clin, Hamamatsu, Shizuoka 4328067, Japan
[4] Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan
关键词
prediction; pharmacokinetics; hemodialysis; end-stage renal disease (ESRD); antibiotic;
D O I
10.1248/bpb.29.1454
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A novel and convenient method to predict the pharmacokinetics of several kinds of antibiotic agents in patients with end-stage renal disease (ESRD) was examined based on the in vitro extraction ratios and pharmacokinetic parameters in healthy volunteers. The dializability of 17 antibiotic agents in 4% human serum albumin solution were determined using a high-performance hemodialytic membrane for clinical use. We assumed that the off-hemodialysis clearance approximated the non-renal clearance, while the on-hemodialysis clearance was considered to be sum of the off-hemodialysis clearance and the hemodialytic clearance. The estimated on- and off-hemodialysis clearances were compared with the ones observed in ESRD patients. In order to confirm the method prospectively, an in vivo pharmacokinetic study was performed in dogs with mercury chloride-induced experimental renal failure. The in vitro extraction ratios of 9 beta-lactams were broadly ranged from 10.9 to 75.6% depending on their physicochemical properties. In contrast, those of the other antibiotics were consistent with their chemical classes: 60.5-63.2% for fluoroquinolone, 48.8-51.1% for aminoglycoside and 18.7-25.6% for glycopeptide. Both the estimated on- and off-hemodialysis clearances of the 17 antibiotics coincided well with the observed values in the literature, regardless of their physicochemical and pharmacokinetic properties. The validity and applicability of this method to three cefems, cefmetazole, cefotaxime and cefoperazone, was prospectively confirmed in the animal study. In conclusion, this new method enables the prediction of the on- and off-hemodialysis clearances of several kinds of antibiotics in ESRD patients from minimal information of their pharmacokinetics in healthy subjects and their in vitro dializability.
引用
收藏
页码:1454 / 1459
页数:6
相关论文
共 50 条
  • [41] Pharmacotherapy of end-stage renal disease
    Schmid, Holger
    Schiffl, Helmut
    Lederer, Stephan R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (04) : 597 - 613
  • [42] Thyroid disease in end-stage renal disease
    Rhee, Connie M.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2019, 28 (06) : 621 - 630
  • [43] Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis
    Lingscheid, Tilman
    Kinzig, Martina
    Krueger, Anne
    Mueller, Nils
    Boelke, Georg
    Tober-Lau, Pinkus
    Muenn, Friederike
    Kriedemann, Helene
    Witzenrath, Martin
    Sander, Leif E.
    Soergel, Fritz
    Kurth, Florian
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (11)
  • [44] Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
    Kosoglou, Teddy
    Kraft, Walter K.
    Kumar, Bharath
    Statkevich, Paul
    Xuan, Fengjuan
    Ma, Lei
    Jennings, Lisa K.
    Schiller, James E.
    Langdon, Ronald B.
    Cutler, David L.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (07) : 1049 - 1056
  • [45] Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease?
    Perez, Renata M.
    Ferreira, Adalgisa S. P.
    Medina-Pestana, Jose O.
    Cendoroglo-Neto, Miguel
    Lanzoni, Valeria P.
    Silva, Antonio Eduardo B.
    Ferraz, Maria Lucia G.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2006, 40 (05) : 444 - 448
  • [46] Multiple-Dose Pharmacokinetics and Pharmacodynamics of N-Acetylcysteine in Patients with End-Stage Renal Disease
    Nolin, Thomas D.
    Ouseph, Rosemary
    Himmefarb, Jonathan
    McMenamin, M. Elizabeth
    Ward, Richard A.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (09): : 1588 - 1594
  • [47] Improving Outcomes in Patients with Lupus and End-Stage Renal Disease
    Inda-Filho, Antonio
    Neugarten, Joel
    Putterman, Chaim
    Broder, Anna
    SEMINARS IN DIALYSIS, 2013, 26 (05) : 590 - 596
  • [48] Depression among patients with end-stage renal disease in hemodialysis
    Silva Junior, Geraldo B.
    Daher, Elizabeth F.
    Buosi, Ana Paula A.
    Lima, Rafael S. A.
    Lima, Mikaelly M.
    Silva, Eveline C.
    Sampaio, Aline M.
    Santana, Joao Moises L.
    Monteiro, Francisco Emmanuel C.
    Araujo, Snia M. H. A.
    PSYCHOLOGY HEALTH & MEDICINE, 2014, 19 (05) : 547 - 551
  • [49] Smoking and hyperparathyroidism in patients with end-stage renal disease (ESRD)
    Tripepi, Giovanni
    Mattace-Raso, Francesco
    Pizzini, Patrizia
    Cutrupi, Sebastiano
    Witteman, Jacqueline
    Zoccali, Carmine
    Mallamaci, Francesca
    JOURNAL OF NEPHROLOGY, 2012, 25 (01) : 75 - 83
  • [50] Characteristics of Elderly Patients with Diabetes and End-Stage Renal Disease
    Goldfarb-Rumyantzev, Alexander S.
    Rout, Preeti
    SEMINARS IN DIALYSIS, 2010, 23 (02) : 185 - 190